Pazopanib is a multi-targeted receptor tyrosine kinase inhibitor that selectively restraining the autophosphorylation of receptors such as VEGFR-2, Kit, and PDGFR-β in renal cell carcinoma (46). Here, PDGFRB is linked to hereditary clear cell renal cell carcinoma.